Semaglutide: a promising new glucagon-like peptide-1 receptor agonist

Affiliations

¹ Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, Liège, B-4000, Belgium; Division of Clinical Pharmacology, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium. Electronic address: andre.scheen@chu.ulg.ac.be.

Comment

André J Scheen. Lancet Diabetes Endocrinol. 2017 Apr.

. 2017 Apr;5(4):236-238.

doi: 10.1016/S2213-8587(17)30012-8. Epub 2017 Jan 17.

¹ Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, Liège, B-4000, Belgium; Division of Clinical Pharmacology, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium. Electronic address: andre.scheen@chu.ulg.ac.be.

No abstract available

Comment on

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Sorli C, et al. Lancet Diabetes Endocrinol. 2017 Apr;5(4):251-260. doi: 10.1016/S2213-8587(17)30013-X. Epub 2017 Jan 17. Lancet Diabetes Endocrinol. 2017. PMID: 28110911 Clinical Trial.